EU Negative on Approving Eisai’s Alzheimer’s Drug Lecanemab
The European Medicines Agency has said that its committee for assessing medicines recommended “not granting a marketing authorization” to Alzheimer’s drug lecanemab.
According to the announcement by the EMA, which is under the European Union, on Friday, the committee pointed out that the effect of lecanemab, developed jointly by Japan’s Eisai Co. and U.S. drugmaker Biogen Inc., in delaying cognitive decline “does not counterbalance” the risk of serious side events, such as bleeding in the brain.






